The content on this site is intended for healthcare professionals only
Dr Manchanda speaks with ecancer at BCGS 2018 about the PROTECTOR study for women with a high risk of developing ovarian cancer.
He describes the aetiology of the disease, and managing the impact of side effects following removal of ovaries with hormone therapy.
Dr Manchanda goes on to describe the staging of the PROTECTOR study, in which fallopian tubes are removed while ovaries remain intact, aiming to balance risk reduction and quality of life for patients.
Transforming cancer care in India: The Access Cancer Care Initiative
Social determinants and survival outcomes in early-onset colorectal cancer in the US
The added value of integrative medicine
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
Best practice in HRRm testing in patients with metastatic prostate cancer
Novel therapies and combinations in ovarian cancer
Genomic testing: Awareness and effective communication between healthcare professionals and patients
